Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer

Lung Cancer

Volumn 39, Issue 1, 2003, Pages 77-84

  Vieitez, J M ^a   Valladares, M ^b   Gracia, M ^c   Gonzalez Baron M ^d   Martin G ^e   Mel, J R ^f   Rodriguez R ^g   Constenla, M ^h   Gomez Aldavari J L ^e   Dominguez S ⁱ   Dorta, J ^e   Garcia Giron C ^j   Lopez R ^k   Sevilla, I ^l   Esteban, E ^a   Anton L M ^b   Pelaez I ^c   Lopez E ^e   Lacave, A J ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c HOSPITAL DE CABUEÑES   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e Complejo Hospitalario ^*

^f The Division of Rheumatology   (Spain)

^g Department of Medical Oncology   (Spain)

^h HOSPITAL MONTECELO   (Spain)

ⁱ HOSPITAL TXAGORRITXU   (Spain)

^j HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^k Instituto de Salud Carlos III   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

more..

Author keywords

Carboplatin; Etoposide; Paclitaxel; Phase II; Small cell lung cancer

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HUMAN; LIVER TOXICITY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; CARBOPLATIN; CARCINOMA, SMALL CELL; ETOPOSIDE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037216505     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00387-2     Document Type: Article

References (36)

1. Murren J, Hellman S, Rosember JA, editors. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins, 2001:983-1018.
2. Vaporcillan A.A., Nasbitt J.C., Lee J.S., Stevens C., Komaki R., Roth J.A. Cancer of the lung. Holland J.F., Frei E. Cancer medicine. 5th ed:2000;1227-1292 BC Decker, Hamilton Ontario Canada.
3. Skarlos D.V., Samantas E., Kosmidis P., et al. Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer. Ann. Oncol. 5:1994;601-607.
4. Ettinger D.S., Finkelstein D.M., Sarma R.P., Johnson D.H. Phase II study of paclitaxel in patients with extensive disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 13:1995;1430-1435.
5. Kirschling R.J., Grill J.P., Marks R.S., et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am. J. Clin. Oncol. 22:(5):1999;517-522.
6. Smit E.F., Fokkema E., Biesma B., et al. A phase II study of paclitaxel in heavely pretreated patients with small-cell lung cancer. Br. J. Cancer. 77:1998;347-351.
7. Gatzemeier U., Jagos U., Kauekek E., et al. Paclitaxel, carboplatin and oral etoposide: a phase II trial in limited stage small cell lung cancer. Semin. Oncol. 24:(s12):1997;149-152.
8. Hainsworth J.D., Gray J.R., Stroup S.L., et al. Paclitaxel, carboplatin and extended-schedule etoposide in the treatment of small cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J. Clin. Oncol. 15:1997;3464-3470.
9. Frey C.M., Frey M.R., Rusell E., Jonhson B.E. Non parametric methods evaluating drug combinations show paclitaxel and etoposide are antagonistic over a range of concentrations. Proc. Am. Assoc. Cancer Res. 35:1994;330. abstr.
10. Perez E.A., Buckwalter C.A. Sequence dependent citotoxicity of Taxol and Etoposide in lung and breast human cancer cell lines. Cancer Chemother. Pharmacol. 4:1998;448-452.
11. Felip E., Massuti B., Camps C., et al. Superiority of sequential vs concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two phase II trials. Clin. Cancer Res. 4:1998;2723-2728.
12. Rowinsky E.K., Citardi M.J., Noe D.A., Donehawer R.C. Sequence-dependent cytotoxic effects due to combinations of cisplatin and antimicrotubule agents taxol and vincristine. J. Cancer Res. Clin. Oncol. 119:1993;727-733.
13. Rowinsky E.K., Gilbert M.R., McGuire W.P., et al. Sequences of Taxol and cisplatin. A phase I and pharmacologic study. J. Clin. Oncol. 9:1991;1692-1703.
14. Miller A.A., Herndon J.E. II, Hollis D.R., et al. Schedule dependency of 21 day oral versus 3 day intrevenous etoposide in combination with intravenous cisplatin in extensive stage small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. J. Clin. Oncol. 13:1995;1871-1879.
15. Ihde D.C., Mulshine J.L., Kramer B.S., et al. Prospective randomised comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J. Clin. Oncol. 12:1994;2022-2034.
16. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS March 1998.
17. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7:1989;1748-1756.
18. WHO Handbook of Reporting Results of Cancer Treatment. Geneva 1979.
19. Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 38:1982;143-151.
20. Kaplan E.L., Meyer P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
21. Lee E.T. Statistical methods for survival data analysis. 1992;Wiley.
22. Armitage P., Berry G. Statistical methods in medical research. 1987;Blackwell Scientific Publications, Oxford.
23. Edmonson J.H., Lagakos S.W., Salawy O.S., et al. Cyclophosphamide and cCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat. Rep. 60:1976;925-930.
24. Lowenbraun S., Bartolucci A., Smalley R.V., et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung cancer. Cancer. 44:1979;406-412.
25. Girling D.J. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicentre randomized trial. Medical Research council lung cancer working party. Lancet. 348:1996;563-566.
26. Souhami R.L., Spiro S.G., Rudal R.M., et al. Five day oral etoposide treatment for advanced small cell lung cancer: randomized comparison with intravenous chemotherapy. J. Natl. Cancer Inst. 89:1998;577-580.
27. Loehrer P.J., Ansari R., Gonin R., et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J. Clin. Oncol. 13:1995;2594-2599.
28. Arriagada R., Chevalier T.L., Pignon J.P., et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N. Engl. J. Med. 329:1993;1848-1852.
29. Skarlos D.V., Samantas E., Briassoulis E., et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann. Oncol. 12:2001;1231-1238.
30. Mavroudis D., Papadakis E., Veslemes E., et al. A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as first-line treatment in patients with small cell lung cancer (SCLC). Ann. Oncol. 12:2001;463-470.
31. Hainsworth J.D., Thompson D.S., Greco A. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J. Clin. Oncol. 13:1995;1609-1614.
32. Hirsch F.R., Osterlind, Jeppesen N., et al. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients. Ann. Oncol. 12:2001;647-653.
33. Greco F.A., Thomas M., Hainsworth J.D. One-hour paclitaxel infusions: review of safety and efficacy. Cancer J. Sci. Am. 5:1999;179-191.
34. Glisson G.S., Kurie J.M., Perez Soler R., et al. Cisplatin, etoposide and paclitaxel in the treatment of patients with extensive small cell lung carcinoma. J. Clin. Oncol. 17:1999;2309-2315.
35. Birch R., Greco F., Hainsworth J., et al. Preliminary results of a randomized study comparing etoposide and carboplatin (EP) with or without paclitaxel (T) in newly diagnosed small cell lung cancer. Semin. Oncol. 24:(Suppl 12):1997;135-137.
36. Gatzemeier U., Von Pawel J., Macha H., et al. A phase III trial of taxol, etoposide phosphate and carboplatin (TEC) versus carboplatin, etoposide phosphate and vincristine (CEV) in previously untreated small cell lung cancer. Proc. ASCO. 19:2000;483.